Warfarin therapy: Tips and tools for better control

Journal of Family Practice

Volumn 60, Issue 2, 2011, Pages 70-75

  Garcia, David A ^a   Schwartz, Michael J ^b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b Health Services at Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING; BODY MASS; CARDIOVASCULAR RISK; DRUG CONTRAINDICATION; DRUG MONITORING; DRUG SAFETY; EMBOLISM; FIRST TRIMESTER PREGNANCY; GENERAL PRACTITIONER; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VALVE PROSTHESIS; HOME CARE; HUMAN; HYPOTHYROIDISM; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; PATIENT EDUCATION; PATIENT MONITORING; PROTHROMBIN TIME; REVIEW; RISK BENEFIT ANALYSIS; SECOND TRIMESTER PREGNANCY; SENESCENCE; SEX; THIRD TRIMESTER PREGNANCY; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM; ARTICLE; DOCTOR PATIENT RELATION; INTERNET; METHODOLOGY; PRACTICE GUIDELINE; SELF CARE;

ANTICOAGULANTS; DRUG MONITORING; HUMANS; INTERNATIONAL NORMALIZED RATIO; INTERNET; PATIENT EDUCATION AS TOPIC; PHYSICIAN-PATIENT RELATIONS; PRACTICE GUIDELINES AS TOPIC; SELF CARE; THROMBOEMBOLISM; WARFARIN;

EID: 79952506452     PISSN: 00943509     EISSN: 15337294     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. International Self-Monitoring Association of Oral Anticoagulated Patients. We motivate patients to take control of their own oral anticoagulation therapy. Available at: http://www.ismaap.org. Accessed January 12, 2011.
2. Alere. Introducing InRatio 2. Available at: www.hemosense. com. Accessed January 25, 2009.
3. US Food and Drug Administration. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation [press release]. October 19, 2010. Available at: http://www.fda.gov/News Events/Newsroom/PressAnnouncements/ucm230241.htm. Accessed January 12, 2011.
4. Garcia DA, Witt DM, Hyleck E, et al. Delivery of optimized anticoagulant therapy consensus statement from the Anticoagulant Forum. Ann Pharmacother. 2008;42:979-988.
5. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):204S-233S. (Pubitemid 39297955)
6. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095-1106. (Pubitemid 40720733)
7. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 suppl):160S-198S. (Pubitemid 351892967)
8. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 suppl):257S-299S.
9. Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) Score. J Am Coll Cardiol. 2011;57:173-180.
10. Beckmann CR. Obstetrics and Gynecology. 4th ed. Baltimore, Md: Lippincott Williams & Wilkins; 2002:58.
11. Garcia D, Regan S, Crowther M, et al. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005;127:2049-2056.
12. Kurnick D, Loebstein R, Farfel Z, et al. Complex drug-drug-disease interactions between amiodarone, warfarin and the thyroid gland. Medicine. 2004;83:107-113. (Pubitemid 38524627)
13. Stephens MA, Self TH, Lancaster D, et al. Hypothyroidism: effect on warfarin anticoagulation. South Med J. 1989;82:1585-1586. (Pubitemid 20015923)
14. Chute JP, Ryan CP, Sladek G, et al. Exacerbation of warfarin-induced anticoagulation by hyperthyroidism. Endocr Pract . 1997;3: 77-79.
15. Kennedy M, Armanious C, Costa M. Dermatologic manifestations of hematologic disease. Emedicine web site. Updated June 25, 2009. Available at: http://emedicine.medscape.com/ article/1096183-overview. Accessed January 14, 2011.
16. Kellett HA, Sawers JS, Boulton FE, et al. Problems of anticoagulation with warfarin in hyperthyroidism. Q J Med. 1986;58:43-51. (Pubitemid 16101940)
17. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition-2005 update. Br J Haematol. 2006;132:277-285. (Pubitemid 43381534)
18. Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis. 1998;5(suppl): 19-24.
19. Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis. 2000;9:283-292. (Pubitemid 30201262)
20. Ansell JE, Buttaro ML, Thomas OV, et al. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Ann Pharmacother. 1997;31:604-615. (Pubitemid 27203962)
21. Palareti G, Legnani C, Guazzaloca G, et al. Risk factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol. 2005;129:72-78. (Pubitemid 40524054)
22. Matchar DB, Jacobson A, Dolor R, et al., for the THINRS Executive Committee and Site Investigators. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010;363:1608-1620.
23. Cromheecke ME, Levi M, Colly LP, et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomized cross-over comparison. Lancet. 2000;356:97-102. (Pubitemid 30438510)
24. Heidinger, KS Bernardo A, Taborski U, et al. Clinical outcome of self-management of oral anticoagulation in patients with atrial fibrillation or deep vein thrombosis. Thromb Res. 2000;98:287-293.
25. Centers for Medicare and Medicaid Services. CMS manual system. Pub 100-04 Medicare claims processing. Transmittal 1562. July 25, 2008. Available at: http://www.cms.gov/transmittals/ downloads/R1562CP.pdf. Accessed January 14, 2011.
26. Weathermon R, Crabb DW. Alcohol and medication interactions. Alcohol Res Health. 1999;23:40-54.
27. Delaney JA, Opatrny L, Brophy JM, et al. Drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ. 2007;177:347-351. (Pubitemid 47339530)
28. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy. Stroke. 2005;36:1588-1593. (Pubitemid 40967537)
29. Philips. Which patients qualify for PT/INR self-testing? Available at: http://www.inrselftest.com/content/clinicians/which-patients-qualify. Accessed January 13, 2011.